Categories: Health

Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close

Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S’s pending acquisition of Catalent, Inc. (Catalent), including expiry of the timing agreement in the US, have been fulfilled. Catalent is a global contract development and manufacturing organisation headquartered in New Jersey (US). The parties are now free to close the transaction, as well as Novo Nordisk’s subsequent acquisition of three Catalent manufacturing sites from Novo Holdings A/S.

The agreement to acquire the three manufacturing sites was announced on 5 February 2024. For further information, please see the company announcement here.

Novo Nordisk now expects the acquisition to be completed in the coming days.

Upon completion, the acquisition is expected to impact the financial outlook as issued on 6 November 2024, with a low single-digit negative impact on operating profit growth and to negatively impact free cash flow with the 11.7 billion USD acquisition price. The ongoing share buyback programme of 20 billion DKK is not impacted.

For 2025, the acquisition is expected to have a mid single-digit negative impact on operating profit growth. The acquisition will be mainly debt-financed, with interest payments negatively impacting net financial items. Novo Nordisk’s capital allocation priorities focus on internal growth investments, including supply chain expansions, dividends as well as external growth opportunities, including acquiring the three manufacturing sites. Consequently, Novo Nordisk is not expecting to initiate a share buyback programme in 2025.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com
Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com
Investors:
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com
Sina Meyer
+45 3079 6656
azey@novonordisk.com
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com
Frederik Taylor Pitter
+1 609 613 0568
fptr@novonordisk.com

Company announcement No 96 / 2024

GlobeNews Wire

Recent Posts

Oregon Tool Appoints Terry Hames as CEO

Hames Promoted from President & CFO PORTLAND, Ore., May 1, 2025 /PRNewswire/ -- Oregon Tool,…

10 minutes ago

Latham Bolsters Antitrust and Competition Practice in Germany

The addition of Dr. Tilman Kuhn upholds Latham's legacy of cutting-edge legal excellence across its…

10 minutes ago

Welcome to the 1V1 Trading Arena: Bybit Blends Gameplay With Real Crypto Wins for Pro and New Users

DUBAI, UAE, April 30, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading…

10 minutes ago

VCTI Launches AI Center of Excellence to Drive Growth Across the Telecom Ecosystem

SOMERSET, N.J., April 30, 2025 /PRNewswire/ -- VCTI, the broadband expansion and network technology experts,…

10 minutes ago

AdCare Hospital Names New Executive Director to Tackle Growing Addiction Crisis Across Massachusetts

WORCESTER, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- As Massachusetts continues to see waves of…

4 hours ago